»PROCESS« China

With the theme of “Helping Protein and mRNA Drugs Innovate and Winning the Global Market”, the seminar was aimed to build a platform for in-depth analyses of the future development of protein and mRNA drugs, explore new models of global cooperation, and assist Shanghai’s biopharmaceuticals in going global for win-win development. A total of around 80 people from the government authorities, pharmaceutical companies and investment institutions attended the seminar to engage in discussions on industry dynamics, the capital market of the biopharmaceutical industry, regulatory policies and other topics. Dr. Susanne Leonhartsberger, Head of WACKER BIOSOLUTIONS, attended the seminar.

In recent years, Chinese pharmaceutical enterprises have been actively exploring international development, and their competitiveness on the global stage has been increasing. Dr. Seidel introduced the latest trends of the global pharma market to the attendees, pointing out that there are signs of recovery on the market whether judging from VC biotech funding or clinical studies. 

"If you look on the market projections, there is a big growth for the technologies and modalities (pDNA and mRNA), so this is one reason why Wacker is active in this area. We believe there will be a lot of companies developing new drugs, and they will need manufacturing specialists like us," he said at the seminar.

He also made an introduction of WACKER and Wacker Biotech and explained to the audience Wacker Biotech's unique advantages as a CDMO.

"What makes us special is that we are very flexible, and we really work very individually with our partners. We have a broad spectrum of services and production sites. We are already dealing with different clients from different countries, also out of the APAC region. We are known for solving the problems of our clients in the CMC area. We are honest and we are delivering on what we promise. Also, we have financial stability which is super important for a CDMO as you don´t want to change your CDMO in later phase. In addition, we have technologies which can reduce the cost of goods---these technologies can add value to your product,” he said.

As a globally operating chemical company headquartered in Munich, Germany, WACKER provides a wide range of services for the biopharma industry ranging from process & analytical development to the GMP manufacturing of biologics for clinical & commercial supply. In this June, WACKER opened an mRNA competence center at its biotech site in Halle (Saale), Germany. The new facility enables the large-scale production of active ingredients based on messenger ribonucleic acid (mRNA), such as anti-Covid mRNA vaccines.

About Wacker Biotech

Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are full-service contract manufacturers of therapeutic proteins, live microbial products (LMPs), plasmid DNA (pDNA), messenger ribonucleic acid (mRNA) and vaccines based on microbial systems. Wacker Biotech’s portfolio extends from strain/process development and analytical testing through to production for clinical and commercial applications. Wacker Biotech operates three GMP-compliant, FDA- and EMA-certified production plants at its Jena and Halle sites in Germany and in Amsterdam in the Netherlands. In addition, Wacker Biotech has had a plant in San Diego (Wacker Biotech US Inc.) since February 2021. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly owned subsidiaries of Wacker Chemie AG.